1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Benign Prostatic Hyperplasia - Pipeline Review, H1 2016

Benign Prostatic Hyperplasia - Pipeline Review, H1 2016

  • May 2016
  • -
  • Global Markets Direct
  • -
  • 128 pages

Benign Prostatic Hyperplasia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Benign Prostatic Hyperplasia - Pipeline Review, H1 2016’, provides an overview of the Benign Prostatic Hyperplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia
- The report reviews pipeline therapeutics for Benign Prostatic Hyperplasia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Benign Prostatic Hyperplasia therapeutics and enlists all their major and minor projects
- The report assesses Benign Prostatic Hyperplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Benign Prostatic Hyperplasia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Benign Prostatic Hyperplasia Overview 10
Therapeutics Development 11
Pipeline Products for Benign Prostatic Hyperplasia - Overview 11
Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis 12
Benign Prostatic Hyperplasia - Therapeutics under Development by Companies 13
Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes 15
Benign Prostatic Hyperplasia - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Benign Prostatic Hyperplasia - Products under Development by Companies 20
Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes 22
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development 23
AndroScience Corporation 23
Aphios Corporation 24
Ausio Pharmaceuticals, LLC 25
BCWorld Pharm Co. Ltd. 26
Chong Kun Dang Pharmaceutical Corp. 27
Dongkook Pharmaceutical Co., Ltd. 28
Euroscreen S.A. 29
Hanmi Pharmaceuticals, Co. Ltd. 30
Jeil Pharmaceutical Co., Ltd. 31
Kaken Pharmaceutical Co., Ltd. 32
Meiji Seika Pharma Co., Ltd. 33
Mezzion Pharma Co. Ltd. 34
Monosol Rx, LLC 35
Nymox Pharmaceutical Corporation 36
Ono Pharmaceutical Co., Ltd. 37
Sihuan Pharmaceutical Holdings Group Ltd. 38
SK Chemicals Co., Ltd. 39
SOM Innovation Biotech SL 40
Sophiris Bio, Inc. 41
Yungjin Pharm. Co., Ltd. 42
Benign Prostatic Hyperplasia - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
(dutasteride + tadalafil) - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
(tadalafil + tamsulosin hydrochloride) - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
ASC-JM.X2 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
AUS-131 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
BCWPE-004 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
BL-214 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
CKD-902 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
ESN-364 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
fadanafil - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
fexapotide triflutate - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
HCP-1303 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
HIP-1402 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
L-1AD3 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
MCS-2 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
NCE-403 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
ONO-8430506 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
S-40542 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
SL-052 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
SOM-2391 - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
SOM-2393 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
Sperol - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
tadalafil - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
talaporfin sodium - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
tamsulosin hydrochloride CR - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
tamsulosin hydrochloride DR - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
tertomotide - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
topsalysin - Drug Profile 90
Product Description 90
Mechanism of Action 90
RandD Progress 90
udenafil - Drug Profile 93
Product Description 93
Mechanism of Action 93
RandD Progress 93
YBH-1603 - Drug Profile 95
Product Description 95
Mechanism of Action 95
RandD Progress 95
YOB-1604 - Drug Profile 96
Product Description 96
Mechanism of Action 96
RandD Progress 96
Benign Prostatic Hyperplasia - Recent Pipeline Updates 97
Benign Prostatic Hyperplasia - Dormant Projects 116
Benign Prostatic Hyperplasia - Discontinued Products 120
Benign Prostatic Hyperplasia - Product Development Milestones 121
Featured News and Press Releases 121
May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting 121
Apr 01, 2015: Nymox Announces Phase 3 BPH Studies 121
Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 121
Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints 122
Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia 122
Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH 123
Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study 124
Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207 124
Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug 125
May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH 126
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2016 11
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Development by Companies, H1 2016 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Comparative Analysis by Unknown Stage Development, H1 2016 19
Products under Development by Companies, H1 2016 20
Products under Development by Companies, H1 2016 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2016 22
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H1 2016 23
Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H1 2016 24
Benign Prostatic Hyperplasia - Pipeline by Ausio Pharmaceuticals, LLC, H1 2016 25
Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 26
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 27
Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016 28
Benign Prostatic Hyperplasia - Pipeline by Euroscreen S.A., H1 2016 29
Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 30
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 31
Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 32
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016 33
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H1 2016 34
Benign Prostatic Hyperplasia - Pipeline by Monosol Rx, LLC, H1 2016 35
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H1 2016 36
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 37
Benign Prostatic Hyperplasia - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 38
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H1 2016 39
Benign Prostatic Hyperplasia - Pipeline by SOM Innovation Biotech SL, H1 2016 40
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H1 2016 41
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 42
Assessment by Monotherapy Products, H1 2016 43
Assessment by Combination Products, H1 2016 44
Number of Products by Stage and Target, H1 2016 46
Number of Products by Stage and Mechanism of Action, H1 2016 48
Number of Products by Stage and Route of Administration, H1 2016 50
Number of Products by Stage and Molecule Type, H1 2016 52
Benign Prostatic Hyperplasia Therapeutics - Recent Pipeline Updates, H1 2016 97
Benign Prostatic Hyperplasia - Dormant Projects, H1 2016 116
Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H1 2016 117
Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H1 2016 118
Benign Prostatic Hyperplasia - Dormant Projects (Contd..3), H1 2016 119
Benign Prostatic Hyperplasia - Discontinued Products, H1 2016 120

List of Figures
Number of Products under Development for Benign Prostatic Hyperplasia, H1 2016 11
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 17
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 43
Assessment by Combination Products, H1 2016 44
Number of Products by Top 10 Targets, H1 2016 45
Number of Products by Stage and Top 10 Targets, H1 2016 45
Number of Products by Top 10 Mechanism of Actions, H1 2016 47
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 47
Number of Products by Routes of Administration, H1 2016 49
Number of Products by Stage and Routes of Administration, H1 2016 49
Number of Products by Molecule Types, H1 2016 51
Number of Products by Stage and Molecule Types, H1 2016 51

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

Proteinuria Treatment Market: By Type (Angiotensin Converting Enzyme (ACE) Inhibitors, Aldosterone Antagonist (i.e., spironolactone), Angiotensin Receptor Blocker (ARB), and Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Proteinuria is a result of an excess of serum proteins in the urine, which can led to renal damage. The most common cause of proteinuria is diabetes. Globally, development the arena of proteomics and ...

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

Benign prostatic hyperplasia (BPH)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Benign prostatic hyperplasia (BPH) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

Endometriosis- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Endometriosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Endometriosis Industry

October 2016 $ 4950

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.